Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Abstract Background Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation of natural killer (NK) cells. Preclinically, pixatimod inhibits heparan...

Full description

Bibliographic Details
Main Authors: Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, Darryn Bampton, Paul Handley, Tomislav Karoli, Fleur Lanksheer, Liwen Lin, Yiping Yang, Keith Dredge
Format: Article
Language:English
Published: BMJ Publishing Group 2018-06-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Pixatimod
PG545
Immunomodulatory
Tumor-associated macrophage
Dendritic cell
NK cell
Online Access:http://link.springer.com/article/10.1186/s40425-018-0363-5

Internet

http://link.springer.com/article/10.1186/s40425-018-0363-5

Similar Items